NO20075058L - Farmasoytiske sammensetninger inneholdende sirlimus og/eller en analog derav - Google Patents

Farmasoytiske sammensetninger inneholdende sirlimus og/eller en analog derav

Info

Publication number
NO20075058L
NO20075058L NO20075058A NO20075058A NO20075058L NO 20075058 L NO20075058 L NO 20075058L NO 20075058 A NO20075058 A NO 20075058A NO 20075058 A NO20075058 A NO 20075058A NO 20075058 L NO20075058 L NO 20075058L
Authority
NO
Norway
Prior art keywords
sirolimus
pharmaceutical compositions
compositions
analog
expected
Prior art date
Application number
NO20075058A
Other languages
English (en)
Inventor
Tomas Norling
Per Holm
Original Assignee
Lifecycle Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lifecycle Pharma As filed Critical Lifecycle Pharma As
Publication of NO20075058L publication Critical patent/NO20075058L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Foreliggende oppfinnelse angår farmasøytiske sammensetninger i partikkelform eller i fast stoff form som omfatter sirolimus (rapamycin) og/eller derivater derav. Sammensetningene fra oppfinnelsen utviser en akseptabel biotilgjengelighet for sirolimus og/eller et derivat og/eller en analog derav. De farmasøytiske sammensetningene fra oppfinnelsen er utformet for å frigjøre sirolimus på en kontrollert måte slik at plasmanivået forblir innen et smalt terapeutisk vindu som eksisterer for denne klassen av substanser. En utvidet frigjøringsprofil, der toppkonsentrasjonen er blitt redusert uten å tape signifikant biotilgjengelighet, sammen med mindre variabel absorpsjon, er forventet å forbedre sikkerhet/effektivitet forholdet til medikamentet. Sammensetningene i følge oppfinnelsen skaffer videre til veie en signifikant redusert mateffekt og en forsinket frigjøring av sirolimus blir forventet å redusere antallet gastrointestinale sideeffekter.
NO20075058A 2005-03-08 2007-10-08 Farmasoytiske sammensetninger inneholdende sirlimus og/eller en analog derav NO20075058L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200500344 2005-03-08
PCT/DK2006/000135 WO2006094507A1 (en) 2005-03-08 2006-03-08 Pharmaceutical compositions comprising sirolimus and/or an analogue thereof

Publications (1)

Publication Number Publication Date
NO20075058L true NO20075058L (no) 2007-11-08

Family

ID=36577478

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075058A NO20075058L (no) 2005-03-08 2007-10-08 Farmasoytiske sammensetninger inneholdende sirlimus og/eller en analog derav

Country Status (10)

Country Link
US (1) US20080275076A1 (no)
EP (1) EP1858511A1 (no)
JP (1) JP2008532953A (no)
CN (1) CN101137365A (no)
AU (1) AU2006222409A1 (no)
BR (1) BRPI0608573A2 (no)
CA (1) CA2599758A1 (no)
MX (1) MX2007010860A (no)
NO (1) NO20075058L (no)
WO (1) WO2006094507A1 (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
EP1952807A1 (en) * 2007-01-24 2008-08-06 LEK Pharmaceuticals D.D. Sirolimus formulation
TWI478712B (zh) * 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
CA2937492C (en) 2008-11-11 2019-08-13 The Board Of Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
EP2470179B1 (en) 2009-08-26 2017-11-29 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Sustained release delivery systems for the prevention and treatment of head and neck cancers
US10391059B2 (en) 2009-11-11 2019-08-27 Rapamycin Holdings, Inc. Oral rapamycin nanoparticle preparations and use
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
WO2011122523A1 (ja) * 2010-03-29 2011-10-06 アステラス製薬株式会社 放出制御医薬組成物
EP2554168B1 (en) 2010-03-29 2018-01-24 Astellas Pharma Inc. Controlled release pharmaceutical composition
US8632979B2 (en) * 2010-11-22 2014-01-21 Albert Einstein College Of Medicine Of Yeshiva University Methods for determining agents that treat or prevent obesity and/or obesity related diseases and methods for treatment therewith
CN102008437B (zh) * 2010-11-23 2012-11-14 赵晨 一种雷帕霉素眼用微乳注射剂及其制备方法和应用
CN102138903B (zh) * 2011-03-17 2012-12-12 苏州特瑞药业有限公司 一种依维莫司固体口服药物组合物
US9265815B2 (en) * 2011-04-29 2016-02-23 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US8912215B2 (en) 2011-12-13 2014-12-16 Everon Biosciences, Inc. Rapamycin composition
NZ630435A (en) * 2012-07-12 2016-11-25 Abbvie Inc Crystalline forms of an hcv inhibitor
EP2968281B1 (en) 2013-03-13 2020-08-05 The Board of Regents of The University of Texas System Mtor inhibitors for prevention of intestinal polyp growth
ES2799185T3 (es) 2013-03-13 2020-12-15 Santen Pharmaceutical Co Ltd Agente terapéutico para la disfunción meibomiana
WO2014144346A1 (en) * 2013-03-15 2014-09-18 The Board Of Regents Of The University Of Texas System Use of inhibitors of mtor to improve vascular functions in apoe4 carriers
JP7028556B2 (ja) 2013-05-03 2022-03-02 セレクタ バイオサイエンシーズ インコーポレーテッド 特定の薬力学的有効期間および免疫寛容の誘発のための抗原を有する免疫抑制剤の送達
CN104248636A (zh) * 2013-06-28 2014-12-31 上海星泰医药科技有限公司 一种西罗莫司制剂及其制备方法
KR102256576B1 (ko) 2013-10-08 2021-05-27 에이아이 테라퓨틱스, 인코포레이티드 림프관평활근종증의 치료를 위한 라파마이신
US20160317560A1 (en) * 2013-11-07 2016-11-03 The University Of North Carolina At Chapel Hill Particles containing phospholipids or bioactive fatty acids and uses thereof
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
EP3104891A1 (en) 2014-02-11 2016-12-21 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
HUP1400075A2 (hu) * 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
PL3125875T3 (pl) 2014-04-04 2023-11-20 AI Therapeutics, Inc. Nadający się do inhalacji preparat rapamycyny do leczenia stanów związanych z wiekiem
MX2017002933A (es) 2014-09-07 2017-05-30 Selecta Biosciences Inc Metodos y composiciones para atenuar las respuestas inmunes del vector de transferencia anti-viral de edicion del gen.
WO2016057712A1 (en) * 2014-10-07 2016-04-14 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
EP3212194A4 (en) 2014-10-29 2018-06-20 University Of Maryland Methods of treating age-related symptoms in mammals and compositions therefor
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
WO2016130645A1 (en) 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
EP3297629A1 (en) 2015-05-20 2018-03-28 Novartis AG Pharmaceutical combination of everolimus with dactolisib
US20160374616A1 (en) * 2015-06-24 2016-12-29 Daqri, Llc Electrode contact quality
US20190290631A1 (en) * 2016-05-27 2019-09-26 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof
EP3544608A1 (en) 2016-11-23 2019-10-02 Novartis AG Methods of enhancing immune response with everolimus, dactolisib or both
WO2018169811A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
US20190250208A1 (en) * 2018-02-09 2019-08-15 Qualcomm Incorporated Apparatus and method for detecting damage to an integrated circuit
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204243B1 (en) * 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
IL111003A0 (en) * 1993-09-30 1994-11-28 American Home Prod Multi-component oral rapamycin formulation
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
CA2230748C (en) * 1997-03-14 2010-08-03 American Home Products Corporation Rapamycin formulations for oral administration
JP4570357B2 (ja) * 2001-07-06 2010-10-27 ライフサイクル ファーマ エー／エス 制御された凝集

Also Published As

Publication number Publication date
US20080275076A1 (en) 2008-11-06
AU2006222409A1 (en) 2006-09-14
CN101137365A (zh) 2008-03-05
CA2599758A1 (en) 2006-09-14
WO2006094507A1 (en) 2006-09-14
JP2008532953A (ja) 2008-08-21
MX2007010860A (es) 2007-11-12
BRPI0608573A2 (pt) 2017-07-25
EP1858511A1 (en) 2007-11-28

Similar Documents

Publication Publication Date Title
NO20075058L (no) Farmasoytiske sammensetninger inneholdende sirlimus og/eller en analog derav
IL189737A0 (en) Pyrazine derivatives, their preparation and pharmaceutical compositions containing them
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
NO20062583L (no) Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
NO20090623L (no) Forbindelser for behandling av proliferative lidelser
NO20064522L (no) Novel pharmaceutical compositions
IL191635A0 (en) Control of cci-779 dosage form stability through control of drug substance impurities
WO2007075901A3 (en) Quinolin- 4 - one derivatives as modulators of abc transporters
PL2371853T3 (pl) Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, kompozycja farmaceutyczna, zastosowanie pochodnej insuliny lub jej farmaceutycznie dopuszczalnej soli oraz sposób leczenia
WO2008079159A3 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
NO20082730L (no) Morfolinopyrimidinderivater og deres anvendelse i terapi
NO20072739L (no) Stabiliserte ramiprilsammensetninger og fremgangsmater for fremstilling
EP2258350A3 (en) Taste masked dosage form containing roflumilast
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2009028891A3 (en) 1,3,5-triazine-2,4,6-triamine compound or pharmaceutical acceptable salt thereof, and pharmaceutical composition comprising the same
WO2010039977A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
NO20091191L (no) Fremgangsmater for behandling av kreft, innbefattende administrering av et vitamin D preparat og et ytterligere terapeutisk middel, og sammensetninger som inneholder de samme
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
NO20074933L (no) Farmasoytisk sammensetning som innbefatter et indolylmaleimidderivat
TNSN07193A1 (en) Pharmaceutical compositions comprising a camptothecin derivate
WO2004112718A3 (en) Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
SI1707564T1 (sl) Indanil-piperazinski derivati, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
WO2008104852A3 (en) Pharmaceutical compositions comprising adsorbate of fenofibrate
MY152044A (en) Adiponectin for treating pulmonary disease
WO2006128120A3 (en) Novel lapachone compounds and methods of use thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application